To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells (MSCs) by intra-articular injection for degenerative knee osteoarthritis.
Between January 2015 and January 2016, 36 patients with moderate or severe degenerative knee osteoarthritis were randomly devided into 2 groups (
All patients of 2 groups received a course of treatment. The patients were followed up for 6 months. After injection, the incidences of pain and swelling in the cell treatment group were significantly higher than those in the control group (
探讨关节腔注射人脐带MSCs治疗退行性膝骨关节炎的安全性及有效性。.
2015年1月-2016年1月，将36例符合选择标准的中重度退行性膝骨关节炎患者纳入研究，随机分为两组（
两组患者均完成1个疗程治疗，均随访6个月。注射后细胞治疗组疼痛、肿胀发生率显著高于对照组（
关节腔注射人脐带MSCs治疗退行性膝骨关节炎可显著改善患者关节功能和生活质量，注射后1个月起效，治疗作用可持续6个月。.
It can significantly improve the joint function and quality of life to use intra-articular injection of human umbilical cord MSCs for treating degenerative knee osteoarthritis. It takes effect after 1 month and the treatment effect can be sustained for 6 months.